Treatment failures and relapses in onychomycosis: A stubborn clinical problem

Dermatology

Volumn 207, Issue 3, 2003, Pages 255-260

  Arrese, Jorge E ^a   Piérard, Gérald E ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

Antifungal; Conidia; Corneofungimetry; Onychomycosis; Relapse

Indexed keywords

ANTIFUNGAL AGENT; ITRACONAZOLE; TERBINAFINE;

CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CLIMATE CHANGE; CLINICAL FEATURE; COMPUTER ANALYSIS; DERMATOPHYTE; DIAGNOSTIC ACCURACY; EMPLOYMENT; FINGER NAIL; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GENERAL PRACTITIONER; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; INFECTION RISK; LIFESTYLE; MEDICAL ASSESSMENT; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; ONYCHOMYCOSIS; PRIORITY JOURNAL; RELAPSE; REVIEW; TINEA CAPITIS; TREATMENT FAILURE; TRICHOPHYTON MENTAGROPHYTES; TRICHOPHYTON RUBRUM; TRICHOPHYTON VIOLACEUM; VITAL STAIN; YEAST CELL;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; BIOPSY, NEEDLE; CONTROLLED CLINICAL TRIALS; FEMALE; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; ONYCHOMYCOSIS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 0142196749     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000073086     Document Type: Review

References (26)

1. Arrese JE, Piérard-Franchimont C, Piérard GE: A plea to bridge the gap between antifungals and the management of onychomycosis. Am J Clin Dermatol 2001;2:281-284.
2. Evans EGV, Sigurgeirsson B: Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION study Group. BMJ 1999;318:1031-1035.
3. Sigurgeirsson B, Olafsson JH, Steinsson JB, Paul C, Billstein S, Evans EG: Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: A 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-357.
4. Arrese JE, Piérard-Franchimont C, Piérard GE: Facing up to the diagnostic uncertainty and management of onychomycoses. Int J Dermatol 1999;38(suppl 2):1-6.
5. Piérard GE, Arrese JE, Pierre S, Bertrand C, Corcuff P, Lévêque JL, Piérard-Franchimont C: Diagnostic microscopique des onychomycoses. Ann Dermatol Venereol 1994;121:25-29.
6. Scherer WP, McCreary JP, Hayes WW: The diagnosis of onychomycosis in a geriatric population: A study of 450 cases in South Florida. J Am Podiatr Med Assoc 2001;91:456-464.
7. Elewski BE: Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol 1996;35:S6-S9.
8. Haldane DJ, Robart E: A comparison of calco-fluor white, potassium hydroxide, and culture for the laboratory diagnosis of superficial fungal infection. Diag Microbiol Infect Dis 1990; 13:337-339.
9. Piérard GE, Arrese JE, De Doncker P, Piérard-Franchimont C: Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol 1996;4:273-277.
10. Gianni C, Morelli V, Cerri A, Greco C, Rossini P, Guiducci A, Braidotti P, Calcaterra R, Papini M: Usefulness of histological examination for the diagnosis of onychomycosis. Dermatology 2001;202:283-288.
11. Arrese JE, Piérard-Franchimont C, Greimers R, Piérard GE: Fungi in onychomycosis: A study by immunohistochemistry and dual flow cytometry. J Eur Acad Dermatol Venereol 1995;4:123-130.
12. Summerbell RC: Epidemiology and ecology of onychomycosis. Dermatology 1997;194(suppl 1):32-36.
13. Ginter G, Rieger E, Heigl K, Propst E: Increasing frequency of onychomycosis: Is there a change in the spectrum of infectious agents? Mycoses 1996;39(suppl 1):118-122.
14. Greer DL: Evolving role of nondermatophytes in onychomycosis. Int J Dermatol 1995;34: 521-524.
15. Ellis DH, Marley JE, Watson AB, Williams TG: Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology 1997;194(suppl 1):40-42.
16. Gupta AK, Cooper EA, MacDonald P, Summerbell RC: Utility of inoculum counting (Walshe and English criteria) in clinical diagnosis of onychomycosis caused by nondermatophytic filamentous fungi. J Clin Microbiol 2001;39:2115-2121.
17. Shuster S: Onychomycosis: Making sense of the assessment of antifungal drugs. Acta Derm Venereol 1998;78:1-4.
18. Shuster S, Baran R: Recurrence of fungal nail disease and the dissociation of relapse from reinfection. Acta Dermatovenerol 2001;81:154-155.
19. Piérard GE: Onychomycosis and other superficial fungal infections of the foot in the elderly: A pan-European survey. Dermatology 2001;202:220-224.
20. De Doncker P, Piérard GE: Acquired nail beading in patients receiving itraconazole: An indicator of faster nail growth? A study using optical profilometry. Clin Exp Dermatol 1994;19:404-406.
21. Roberts DT, Evans EG: Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol 1998;138:189-190.
22. Piérard GE, Piérard-Franchimont C, Arrese JE: The boosted oral antifungal treatment for onychomycosis beyond the regular itraconazole pulse dosing regimen. Dermatology 2000;200:185-187.
23. Piérard GE, Piérard-Franchimont C, Arrese JE: The boosted antifungal topical treatment (BATT) for onychomycosis. Med Mycol 2000;38:391-392.
24. Bradley MC, Leidich S, Isham N, Elewski BE, Ghannoum MA: Antifungal susceptibilities and genetic relatedness of serial Trichophytum rubrum isolates from patients with onychomycosis of the toenail. Mycoses 1999;2:105-110.
25. Pírard GE, Arrese JE, De Doncker P: Antifungal activity of itraconazole and terbinafine in human stratum corneum: A comparative study. J Am Acad Dermatol 1995;32:429-435.
26. Arrese JE, De Doncker P, Odds F, Piérard GE: Reduction in the growth of non-dermatophyte moulds by itraconazole: Evaluation by corneofungimetry bioassay. Mycoses 1998;41:461-465.